Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

1(25.0%)

Phase 2

1(25.0%)

N/A

1(25.0%)

Phase 4

1(25.0%)

4Total

Phase 1(1)

Phase 2(1)

N/A(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT01139151Phase 1Completed

4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies

Role: collaborator

NCT01283906Phase 4Completed

A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients

Role: lead

NCT00998023Not ApplicableCompleted

Patient Comfort With Vascular Closure

Role: collaborator

NCT01083875Phase 2Completed

Study to Determine the Effects Treatment With Amlexanox 0.5% Oral Rinse Solution on Oral Mucositis Associated With Radiation Therapy for Cancer of the Head and Neck Region

Role: lead

All 4 trials loaded